Current pharmaceutical design of antituberculosis drugs: Future perspectives

Alejandro Speck-Planche, Marcus Tulius Scotti, Vicente de Paulo-Emerenciano

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

63 Citas (Scopus)

Resumen

The increasing resistance of Mycobacterium tuberculosis to the existing drugs has alarmed the worldwide scientific community. In an attempt to overcome this problem computer-aided drug design has provide an extraordinary support to the different strategies in drug discovery. There are around 250 biological receptors such as enzymes that can be used in principle, for the design of antituberculosis compounds that act by a specific mechanism of action. Also, there more than 5000 compound available in the literature, and that constitute important information in order to search new molecular patterns for the design of new antituberculosis agents. The purpose of this paper is to explored the current state of drug discovery of antituberculosis agents and how the different strategies supported by computeraided drug design methods has influenced in a determinant way in the design of new molecular entities that can result the future antituberculosis drugs.

Idioma originalInglés
Páginas (desde-hasta)2656-2665
Número de páginas10
PublicaciónCurrent Pharmaceutical Design
Volumen16
N.º24
DOI
EstadoPublicada - 2010
Publicado de forma externa

Huella

Profundice en los temas de investigación de 'Current pharmaceutical design of antituberculosis drugs: Future perspectives'. En conjunto forman una huella única.

Citar esto